The burden of cardiovascular disease in the CKD patient
=======================================================

The prevalence of chronic kidney disease (CKD) is steadily increasing in the United States, with approximately 8 million individuals afflicted with the disease and 300,000 of them requiring renal replacement therapy.[@b1-ijnrd-5-165] While studies show that CKD eventually progresses to the point of needing renal replacement therapy, the majority of patients die of cardiovascular disease prior to reaching end-stage renal disease (ESRD).[@b2-ijnrd-5-165] In fact, cardiovascular disease is the primary cause of mortality in these patients.[@b3-ijnrd-5-165] Therefore, research is now being focused on cardiovascular prevention strategies specific to this patient population.

Management of hyperlipidemia (HL) has long been recognized as one of the cornerstones of primary and secondary prevention in coronary artery disease. Low- density lipoprotein (LDL) reduction is known to decrease mortality in the general population.[@b4-ijnrd-5-165],[@b5-ijnrd-5-165] However, the impact of treating HL in CKD has been less clear. Given the wealth of data on the mortality benefit of 3-hydroxy-3-methylglutaryl-coenzyme A inhibitors (ie, statins) in the general population, this group of drugs has garnered the most attention. Subgroup analyses of several statin studies have suggested that patients with predialysis CKD do see a mortality benefit from initiation of a statin.[@b6-ijnrd-5-165],[@b7-ijnrd-5-165] In contrast, two large prospective randomized trials, Die Deutsche Diabetes Dialyse Studie (4D)[@b8-ijnrd-5-165] and A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis (AURORA)[@b9-ijnrd-5-165] found no benefit of statins in ESRD patients. These data suggest that treatment of HL may be more beneficial in predialysis CKD patients than in those with ESRD. It has been suggested that the mechanism of cardiovascular mortality in ESRD patients may be different from that of predialysis CKD patients or the general population. Others have posited that atherosclerosis may be too far advanced once patients reach ESRD.[@b10-ijnrd-5-165],[@b11-ijnrd-5-165]

Pathophysiology of dyslipidemia in chronic kidney disease
=========================================================

Studies suggest that the pathophysiology of dyslipidemia in those with CKD may be different than that of the general population. Changes in a number of key enzymes and receptors in CKD result predominantly in dysregulation of high-density lipoprotein (HDL) and triglyceride metabolism. [@b12-ijnrd-5-165] Reduction in apoprotein (Apo)A-I and ApoA-II leads to low HDL cholesterol levels. Chronic inflammation also contributes to low HDL cholesterol levels by reducing plasma albumin, which serves as a carrier of cholesterol from peripheral tissues to HDL.[@b13-ijnrd-5-165] An increase in ApoC-III levels in CKD results in elevation in triglycerides by inhibiting lipoprotein lipase, an enzyme that breaks down triglyceride-rich particles.[@b13-ijnrd-5-165] While a reduction in HDL cholesterol and an elevation in triglycerides are common lipid disturbances in CKD, LDL cholesterol is often normal in these patients in the absence of nephrotic syndrome.[@b14-ijnrd-5-165],[@b15-ijnrd-5-165]

Those with ESRD are known to have particularly low plasma cholesterol levels. There is some thought that this signifies intense inflammation, which could be one of the primary drivers of increased cardiovascular disease risk in this group. Although LDL levels are lower in these patients, they "tend to be smaller, denser, and therefore more atherogenic,"[@b15-ijnrd-5-165],[@b16-ijnrd-5-165] so it remains that LDL cholesterol may still play a vital role in cardiovascular disease in these patients.[@b16-ijnrd-5-165] Given the potentially unique pathophysiology of cardiovascular disease in ESRD patients, conventional lipid management for primary and secondary prevention may not prove to be as beneficial in this group as the general population. This may partially explain the results seen in the 4D and AURORA trials discussed earlier. The pathophysiology of dyslipidemia and cardiovascular disease in earlier stages of CKD is less clear, but is thought to be more closely related to that of the general population. Therefore, this review will predominantly focus on the impact of HL management, specifically with ezetimibe and simvastatin, on predialysis CKD.

Ezetimibe and simvastatin in the general population
===================================================

Ezetimibe is a Niemann--Pick C1-like 2 protein blocker that potently inhibits the absorption of cholesterol from the gastrointestinal and biliary systems.[@b17-ijnrd-5-165] Because of the drug's good safety profile[@b18-ijnrd-5-165] as well as its reported significant reduction in markers thought to impact cardiovascular outcomes, such as LDL and C-reactive protein (CRP),[@b19-ijnrd-5-165] it was initially hailed as an important first-line addition to HL management. The addition of ezetimibe to a statin has since become the focus of a number of recent studies. Pearson et al[@b19-ijnrd-5-165] identified patients with primary HL and compared the degree of LDL reduction for those treated with ezetimibe and simvastatin versus simvastatin versus atorvastatin versus placebo. They found a significant reduction in LDL with simvastatin and ezetimibe versus simvastatin or atorvastatin alone, regardless of the dose of statin. In the pooled analysis, there was a 52.5% reduction in LDL in the ezetimibe--simvastatin group versus 38% in the simvastatin group (*P* = \<0.001). Similar findings were noted in the ezetimibe--atorvastatin versus atorvastatin groups (53.4% vs 45.3%, respectively; *P* \< 0.001). They also noted significant decreases in CRP. Although the study showed a significant decrease in LDL and CRP levels, it did not evaluate the impact of the addition of ezetimibe on major cardiovascular end points.

Another study, the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial,[@b20-ijnrd-5-165] enrolled 1873 patients with mild to moderate aortic stenosis and randomized them to either 40 mg of simvastatin and 10 mg ezetimibe or placebo. They found a statistically significant decrease in ischemic cardiovascular events in the treatment arm, but noted that this was mainly due to a smaller number of patients under-going coronary artery bypass grafting in this group. It did not answer the question of the impact of adding ezetimibe to a statin versus using a statin alone, given there was no simvastatin arm of the trial. Therefore, despite the reduction of LDL seen with the addition of ezetimibe, these studies have yet to show further cardiovascular mortality benefit of ezetimibe in addition to a statin versus a statin alone in the general population.[@b20-ijnrd-5-165],[@b21-ijnrd-5-165]

The Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial[@b21-ijnrd-5-165] sought to evaluate further the effect of ezetimibe on major adverse cardiovascular events. The study included 720 patients with familial hypercholesterolemia and stratified them to 80 mg of simvastatin and 10 mg of ezetimibe versus 80 mg of simvastatin alone and measured the intima-media thickness (IMT) over a 24-month period. Studies have shown IMT to be a valid surrogate marker for major adverse cardiovascular events, including stroke, angina, and myocardial infarction (MI).[@b22-ijnrd-5-165],[@b23-ijnrd-5-165] The researchers found no statistically significant difference in progression of IMT between the treatment arms, although they again demonstrated a statistically significant reduction in LDL, CRP, and triglyceride levels. The authors of ENHANCE suggest that the results may be due to a "ceiling effect," in which there is little added benefit beyond what is provided by a high-dose statin alone. They also provide several other mechanisms by which statins may slow progression of atherosclerosis outside of LDL reduction. Studies have shown a small albeit significant reduction in blood pressure with incremental increased reduction with increasing blood pressure.[@b24-ijnrd-5-165] There is also an anti-inflammatory effect and an improvement in endothelial function that has been observed in scientific models.[@b25-ijnrd-5-165] Data also suggest that statins may have beneficial effects on CKD not related to LDL reduction, which will be discussed in a later section.

The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)[@b26-ijnrd-5-165] should help answer the question of the utility of adding ezetimibe to a statin. Scheduled to be completed sometime in 2013, IMPROVE-IT has enrolled approximately 18,000 patients (including patients with CKD) stabilized after acute coronary syndrome and randomized them to receive either simvastatin 40 mg or simvastatin 40 mg plus ezetimibe 10 mg. The primary end points of treatment will be the first occurrence of cardiovascular death, nonfatal MI, rehospitalization for unstable angina, coronary revascularization within 30 days of presentation with acute coronary syndrome, or stroke. The goal of the study is ultimately to determine the cardiovascular mortality benefit of adding ezetimibe to current lipid therapy and also to evaluate the impact of further lowering of LDL. It should be noted that patients enrolled in the trial are already at their recommended LDL goal.

Ezetimibe and simvastatin in chronic kidney disease
===================================================

Currently, the Study of Heart and Renal Protection (SHARP) trial[@b27-ijnrd-5-165] is the only study looking specifically at the impact of aggressive LDL-lowering combination therapy with ezetimibe and simvastatin on cardiovascular clinical outcomes in CKD patients. The study was a randomized double-blinded trial that enrolled patients 40 years and older with CKD (including ESRD patients) and an average LDL of approximately 108 mg/dL. They initially randomized 9438 patients to simvastatin 20 mg plus ezetimibe 10 mg versus simvastatin 20 mg versus placebo. Patients were randomized in this manner for 1 year to determine the safety of ezetimibe plus simvastatin in these patients. After 1 year, the majority of the patients in the simvastatin group were rerandomized to simvastatin 20 mg plus ezetimibe 10 mg or placebo and followed for an average of 4 years. The goal LDL reduction was 1 mmol/L (or 39 mg/dL) based on previous data that showed this would result in a one-fifth reduction in cardiovascular events.[@b28-ijnrd-5-165]

Recent studies demonstrate that more aggressive LDL reduction with high-dose statins leads to improved cardiovascular outcomes in the general population.[@b6-ijnrd-5-165],[@b29-ijnrd-5-165]--[@b31-ijnrd-5-165] Although research demonstrates high-dose statins to be safe and effective in the general population,[@b32-ijnrd-5-165] there is general concern among practitioners regarding the safety of higher doses in CKD patients. Guidelines for therapy indicate that statins with minimal renal excretion (ie, pravastatin, atorvastatin, simvastatin) do not need to be dose-adjusted in predialysis CKD patients.[@b13-ijnrd-5-165] However, there have been no studies to date looking at high-dose statins specifically in CKD patients. As previously mentioned, the addition of ezetimibe to a statin also results in a significantly greater reduction in LDL.[@b33-ijnrd-5-165] Therefore, in the SHARP study the decision was made to use the combination of ezetimibe and simvastatin to achieve aggressive LDL reduction,[@b33-ijnrd-5-165] due to concerns for myopathy and other potential side effects with high-dose statin therapy.

The initial goal of the study was not necessarily to determine the efficacy of the combination of ezetimibe and simvastatin on outcomes in CKD, but to determine the impact of LDL reduction on outcomes as renal impairment progresses. The authors state that "when eGFR \[estimated glomerular filtration rate\] falls below 30 mL/min, a different cardiovascular pathology emerges, with vascular stiffness and calcification, structural heart disease, sympathetic overactivity contributing to an increasing risk of cardiac arrhythmia and heart failure."[@b27-ijnrd-5-165],[@b34-ijnrd-5-165] The potential differences in cardiovascular mortality between the general population and those with CKD were highlighted in the 4D trial,[@b8-ijnrd-5-165] in which 21% of the cardiac deaths were due to MI in the general population versus 59% from sudden cardiac death in the ESRD group. The authors suggested that dysrhythmias may be the major cause of cardiovascular mortality in those with CKD (at least in ESRD patients), and therefore aggressive lipid management may not improve outcomes in these patients.

The study found that ezetimibe plus simvastatin resulted in a statistically significant decrease in major atherosclerotic events versus placebo (11.3% versus 13.4%; relative risk \[RR\] 0.83, *P* = 0.0021). Major atherosclerotic events included coronary events (nonfatal MI and coronary death), nonhemorrhagic stroke, or revascularization procedure. When analyzed separately, there was no statistically significant difference in coronary events, although there was a difference in nonhemorrhagic stroke and revascularization procedures. The authors note that the study was not powered sufficiently to look at these atherosclerotic event categories separately. When the results were analyzed for those on dialysis and those not on dialysis, there was no heterogeneity between groups (χ^2^ = 1.34, *P* = 0.25), although there was a statistically significant difference in atherosclerotic events in the nondialysis patients (RR = 0.78, confidence interval 0.67--0.91), whereas the difference did not reach statistical difference in the dialysis patients (RR = 0.90, confidence interval 0.75--1.08). There was also a trend towards decreased atherosclerotic events in the intervention group when patients were stratified by GFR.

Based on these results, the authors concluded that simvastatin 20 mg plus ezetimibe 10 mg "safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease." The study also suggests that the benefit of treating hyperlipidemia is seen across various degrees of CKD, although the outcomes typically evaluated (ie, coronary events categorized as nonfatal MI and cardiovascular-related death) were part of a greater composite end point and did not show statistical significance alone.

Given the study was underpowered specifically for coronary events, we can conclude that there was a trend towards a significant decrease in these types of events when aggressively treating hyperlipidemia in CKD patients. It does not, however, give an indication of the benefits of the addition of ezetimibe to simvastatin, given ezetimibe and simvastatin were compared to placebo alone. If the trial had continued with the initial inclusion of simvastatin alone, the study may have given more insight into this question. There is also the question of whether statins work outside of LDL reduction in CKD patients. Some studies indicate a decrease in proteinuria in CKD patients treated with statins, thereby delaying the progression of disease, although the data on this have been mixed.[@b35-ijnrd-5-165],[@b36-ijnrd-5-165] Results from SHARP suggest that those with higher baseline urinary albumin:creatinine ratios (\>30 mg/g) saw a greater benefit of simvastatin plus ezetimibe versus placebo alone. This suggests that statins may play a role in delaying progression of CKD, although this requires further investigation.

Future directions
=================

The SHARP trial suggests that there is a role for treating hyperlipidemia across all spectrums of CKD. However, there are still lingering questions as to whether the benefits of statins are due to other mechanisms beyond their lipid-lowering effects, making the utility of adding ezetimibe uncertain. Regardless of the questionable benefit of adding ezetimibe to a statin, ezetimibe does play a role in current management. For those patients who cannot tolerate high-dose statins and/or cannot reach their LDL goal, the addition of ezetimibe may prove beneficial, particularly given its safety profile in CKD.

There has been no study of the impact of ezetimibe plus a statin versus a statin alone on CKD patients, although the ongoing IMPROVE-IT[@b26-ijnrd-5-165] is supposed to provide further insight into this question. Results of this trial will provide more guidance as to how this drug combination should be used in primary and secondary prevention of cardiovascular disease in the general population. The expected subgroup analysis of CKD patients will also provide insight into how this drug combination plays a role in cardiovascular disease prevention in CKD patients.
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